Bevacizumab Addition in Neoadjuvant Treatment Increases the Pathological Complete Response Rates in Patients with HER-2 Negative Breast Cancer Especially Triple Negative Breast Cancer: A Meta-Analysis

• Xuelei Ma ,

  Contributed equally to this work with: Xuelei Ma, Xiaoshan Wang, Jingwen Huang, Yingtai Chen

  Affiliation State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan, China

  ⨯
• Xiaoshan Wang ,

  Contributed equally to this work with: Xuelei Ma, Xiaoshan Wang, Jingwen Huang, Yingtai Chen

  Affiliation Department of Clinical Oncology, Sichuan Provincial People’s Hospital, Chengdu, Sichuan, China

  ⨯
• Jingwen Huang ,

  Contributed equally to this work with: Xuelei Ma, Xiaoshan Wang, Jingwen Huang, Yingtai Chen

  Affiliation Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China

  ⨯
• Yingtai Chen ,

  Contributed equally to this work with: Xuelei Ma, Xiaoshan Wang, Jingwen Huang, Yingtai Chen

  Affiliation Department of Abdominal Surgery, Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical Collage, Beijing, China

  ⨯
• Jing Zhang,

  Affiliation Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China

  ⨯
• Binglan Zhang,

  Affiliation State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan, China

  ⨯
• Changle Shi,

  Affiliation Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China

  ⨯
• Lei Liu

  * E-mail: liuleihx@gmail.com

  Affiliation Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China

  ⨯